Exact Sciences Corp. (NASDAQ:EXAS) shares are dropping after the company reported its third-quarter results after Tuesday's closing bell. Here's a look at the details.
The Details: Exact Sciences reported quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million missed the consensus estimate of $717.66 million.
“The Exact Sciences’ team is helping eradicate cancer while strengthening our platform and growing our business efficiently,” said Kevin Conroy, CEO of Exact Sciences.
“During the third quarter, we delivered test results to more patients than ever before, improved profitability, and achieved key milestones in our pipeline of innovative cancer diagnostics. While we have made progress, our execution during the third quarter and updated outlook for the full year don’t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong,” Conroy added.
Read Next: Trump Media Stock Volatile On Election Eve As Polls, Betting Markets Predict Tight White House Race
Outlook: Exact Sciences sees fiscal year 2024 total revenue in a range of $2.73 billion to $2.75 billion, below the $2.83 billion estimate.
EXAS Price Action: According to Benzinga Pro, Exact Sciences shares are down 27.98% after-hours at $51.50 at the time of publication Tuesday.
Read Also:
Photo: Courtesy of Exact Sciences Corporation
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。